We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effective induction of melanoma-antigen-specific CD8<sup>+</sup> T cells via V γ9 γδT cell expansion by CD56<sup>high+</sup> Interferon- α-induced dendritic cells.
- Authors
Nieda, Mie; Terunuma, Hiroshi; Eiraku, Yuuta; Deng, Xuewen; Nicol, Andrew J.
- Abstract
Dendritic cells (DCs) can be differentiated from CD14+ monocytes in the presence of interferon- α (IFN α) and granulocyte/macrophage-colony stimulating factor (GM-CSF) in vitro and are known as IFN-DCs. Circulating blood CD56+ cells expressing high levels of CD14, HLA-DR and CD86 have been shown to spontaneously differentiate into DC-like cells in vitro after their isolation from blood. We show here that IFN-DCs expressing high levels of CD56 (hereafter, CD56high+ IFN-DCs) can be differentiated in vitro from monocytes obtained as adherent cells from healthy donors and patients with metastatic melanoma. These cells expressed high levels of CD14, HLA-DR and CD86 and possessed many pseudopodia. These CD56high+ IFN-DCs may be an in vitro counterpart of the circulating CD56+ CD14+ CD86+ HLA-DR+ cells in blood. Conventional mature DCs differentiated from monocytes as adherent cells in the presence of GM-CSF, IL-4 and TNF- α (hereafter, mIL-4DCs) did not express CD56 or CD14. In contrast to mIL-4DCs, the CD56high+ IFN-DCs exhibited a stronger capacity to stimulate autologous CD56+ V γ9 γδT cells highly producing IFN γ in the presence of zoledronate and IL-2. The CD56high+ IFN-DCs possessing HLA-A*0201 effectively induced Mart-1-modified melanoma peptide (A27L)-specific CD8+ T cells through preferential expansion of CD56+ V γ9 γδT cells in the presence of A27L, zoledronate and IL-2. Vaccination with CD56high+ IFN-DCs copulsed with tumor antigens and zoledronate may orchestrate the induction of various CD56+ immune cells possessing high effector functions, resulting in strong immunological responses against tumor cells. This study may be relevant to the design of future clinical trials of CD56high+ IFN-DCs-based immunotherapies for patients with melanoma.
- Subjects
DENDRITIC cells; GRANULOCYTE-macrophage colony-stimulating factor; ZOLEDRONIC acid; IMMUNOTHERAPY; MELANOMA; THERAPEUTICS
- Publication
Experimental Dermatology, 2015, Vol 24, Issue 1, p35
- ISSN
0906-6705
- Publication type
Article
- DOI
10.1111/exd.12581